Pentoxifylline as adjuvant therapy in the treatment of major depressio

Phase 3

Recruiting

• Conditions: Major Depressive Disorder.; Major depressive disorder, single episode, moderate; F32.1

• Registration Number: IRCT20090117001556N116
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Presence of Major Depressive Disorder based on DSM-5 criteria
Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19

Exclusion Criteria

Presence of psychosis
Any other mental disorder
Hypothyroidism
Cardiovascular disease
Pregnancy or nursing women
Renal failure
Allergy to Theophylline, Aminophylline, and pentoxyfylline
Hepatic failure
Peptic ulcer
Receiving antiplatelets agents or anticoagulants
Receiving NSAIDs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: By Hamiltion Depression Rating Scale 17-Item.